CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

CVRx, a medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The management team's pre-recorded fireside chat is scheduled for November 22, 2021, at 10:00 a.m. ET, accessible via their investor relations page at ir.cvrx.com.

CVRx is known for Barostim™, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms, receiving both the FDA Breakthrough Device designation and CE Mark for its effectiveness.

MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

The Company’s pre-recorded fireside chat will be available on Monday, November 22, 2021 at 10:00 a.m. Eastern Time. Interested parties may access the webcast on the investor relations page of the Company’s website at ir.cvrx.com.

About CVRx, Inc.
CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark Klausner or Mike Vallie
ICR Westwicke
ir@cvrx.com

Media Contact:

Lisa Murray
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
lisa@trevicomm.com

FAQ

What is the purpose of CVRx's participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference?

CVRx's management team will showcase their innovative neuromodulation solutions and discuss the company's advancements in treating cardiovascular diseases.

When will CVRx's fireside chat at the Piper Sandler Conference take place?

The fireside chat is scheduled for November 22, 2021, at 10:00 a.m. Eastern Time.

Where can I access CVRx's webcast for the conference?

The webcast can be accessed on the investor relations page of CVRx's website at ir.cvrx.com.

What is Barostim and its significance in heart failure treatment?

Barostim is the first FDA-approved neuromodulation device that helps reduce heart failure symptoms by stimulating baroreceptors in the carotid artery.

Has Barostim received any designations or approvals?

Yes, Barostim has received the FDA Breakthrough Device designation and is FDA-approved for heart failure treatment in the U.S. It also holds a CE Mark for use in the European Economic Area.